A festschrift in honor of Ian MThompson Jr. , MD. Urol Oncol. 2025 Jul; 43(7):423-435. . View in PubMed

Combined Transcriptomic and Epitranscriptomic Profiling Identifies THBS1 as A Regulator of Enzalutamide Resistance in Prostate Cancer Cancer Heterog Plast. 2025; 2(2). . View in PubMed

Artificial Intelligence and Radiomics Applied to Prostate Cancer Bone Metastasis Imaging: A Review iRadiology. 2024 Dec; 2(6):527-538. . View in PubMed

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer JAMA Netw Open. 2024 Oct 01; 7(10):e2437871. . View in PubMed

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial Eur Urol. 2024 Oct; 86(4):297-300. . View in PubMed

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel Prostate Cancer Prostatic Dis. 2024 Sep; 27(3):566-570. . View in PubMed

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel Eur Urol. 2024 Feb; 85(2):171-176. . View in PubMed

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer Clin Cancer Res. 2024 01 17; 30(2):444-449. . View in PubMed

m6A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer NAR Cancer. 2023 Dec; 5(4):zcad054. . View in PubMed

Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314 Eur Urol Oncol. 2023 10; 6(5):516-524. . View in PubMed

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695) Eur Urol. 2023 09; 84(3):341-347. . View in PubMed

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial) J Clin Oncol. 2023 06 20; 41(18):3352-3362. . View in PubMed

External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer Mol Cancer Ther. 2022 12 02; 21(12):1857-1861. . View in PubMed

Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer Curr Oncol Rep. 2022 10; 24(10):1287-1298. . View in PubMed

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) J Clin Oncol. 2022 10 01; 40(28):3301-3309. . View in PubMed

Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time Sci Rep. 2022 04 01; 12(1):5518. . View in PubMed

FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer Cancers (Basel). 2022 Mar 28; 14(7). . View in PubMed

Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis Int J Mol Sci. 2022 Feb 25; 23(5). . View in PubMed

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) Clin Cancer Res. 2021 05 01; 27(9):2435-2441. . View in PubMed

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) Clin Cancer Res. 2021 04 01; 27(7):1967-1973. . View in PubMed

Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype Int J Cancer. 2020 06 01; 146(11):3065-3076. . View in PubMed

Cancer transcriptomic profiling from rapidly enriched circulating tumor cells Int J Cancer. 2020 05 15; 146(10):2845-2854. . View in PubMed

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)Clin Genitourin Cancer. 2019 08; 17(4):241-247. e1. . View in PubMed

Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research Urol Oncol. 2019 05; 37(5):313-317. . View in PubMed

Multiparametric liquid biopsy analysis in metastatic prostate cancer JCI Insight. 2019 03 07; 4(5). . View in PubMed

Current status of liquid biopsies for the detection and management of prostate cancer Cancer Manag Res. 2019; 11:5271-5291. . View in PubMed

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. . View in PubMed

Development and Application of Liquid Biopsies in Metastatic Prostate Cancer Curr Oncol Rep. 2018 03 23; 20(4):35. . View in PubMed

Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond Cancer Treat Res. 2018; 175:87-104. . View in PubMed

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421 Cancer Treat Res Commun. 2018; 16:18-23. . View in PubMed

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421 Clin Genitourin Cancer. 2017 12; 15(6):635-641. . View in PubMed

The evolution of chemotherapy for the treatment of prostate cancer Ann Oncol. 2017 Nov 01; 28(11):2658-2669. . View in PubMed

Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine Front Oncol. 2017; 7:6. . View in PubMed

Telomere and Telomerase Therapeutics in Cancer Genes (Basel). 2016 May 26; 7(6). . View in PubMed

AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth Prostate. 2016 May; 76(6):597-608. . View in PubMed

Editorial Comment J Urol. 2015 Sep; 194(3):798. . View in PubMed

Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy J Natl Cancer Inst. 2015 Jul; 107(7). . View in PubMed

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial Int J Cancer. 2015 Apr 15; 136(8):1856-62. . View in PubMed

Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther. 2014 Nov; 14(11):1257-60.. View in PubMed

New prostate cancer drugs: extending and improving life Lancet Oncol. 2014 Sep; 15(10):1052-4. . View in PubMed

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer J Clin Oncol. 2014 Apr 10; 32(11):1136-42. . View in PubMed

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421 J Natl Cancer Inst. 2014 Apr; 106(4):dju013. . View in PubMed

Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/ß-catenin/CBP pathway Int J Cancer. 2014 Jan 01; 134(1):43-54. . View in PubMed

Circulating tumor cells in prostate cancer Cancers (Basel). 2013 Dec 04; 5(4):1676-90. . View in PubMed

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. . View in PubMed

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial Lancet Oncol. 2013 Aug; 14(9):893-900. . View in PubMed

Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore Ann Oncol. 2013 Jul; 24(7):1717-1720. . View in PubMed

Perillyl alcohol for the treatment of temozolomide-resistant gliomas Mol Cancer Ther. 2012 Nov; 11(11):2462-72. . View in PubMed

Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference Prostate. 2011 Sep 15; 71(13):1390-400. . View in PubMed

Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype Mol Cancer Ther. 2011 Jun; 10(6):938-48. . View in PubMed

Telomerase targeted therapy in cancer and cancer stem cells Clin Adv Hematol Oncol. 2011 Jun; 9(6):442-55. . View in PubMed

A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter Cancer Res. 2010 Aug 15; 70(16):6420-6. . View in PubMed

Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo Mol Cancer Ther. 2010 Feb; 9(2):438-49. . View in PubMed

Targeted therapy in renal cancer Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. . View in PubMed

Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells Cancer Res. 2006 Jun 01; 66(11):5763-71. . View in PubMed

Cortical variability and asymmetry in normal aging and Alzheimer's disease Cereb Cortex. 1998 Sep; 8(6):492-509. . View in PubMed

Sulcal variability in the Alzheimer's brain: correlations with cognition Neurology. 1998 Jan; 50(1):145-51. . View in PubMed